Skip to content

Nurix

Inside The Science
Advancing Our Pipeline
- Pipeline
- Clinical Trials
Learn About Us
Work at Nurix
- Our Culture
- Explore Jobs

Nurix

Inside The Science
Advancing Our Pipeline
- Pipeline
- Clinical Trials
Learn About Us
Work at Nurix
- Our Culture
- Explore Jobs

Role of Ternary Complex Formation and Ubiquitylation Assays in Early Protein Degrader Discovery

By AldenMC Production / December 15, 2023

Post navigation

ASH Event Presentation 2023

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

WHERE SCIENCE EXPANDS POSSIBILITIES

Inside The Science

DEL-AI Discovery Engine
Targeted Protein Degradation
Resource Library

Advancing Our Pipeline

Pipeline
Clinical Trials

Learn About Us

Our Story
Leadership
Partnering
Contact Us

Work at Nurix

Our Culture
Explore Jobs

For Investors

News & Events
Financial Information
Stock Information
Corporate Governance
FAQs
Investor Contact

For Patients

Resources

©2025 Nurix Therapeutics, Inc.

You are now leaving the nurixtx.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel

Continue